hepatitis C virus genotype

hepatitis C virus genotype

genetic heterogeneity and divergence in the viral sequences produce at least six genotypes of HCV. Genotypes cluster geographically (e.g., genotypes 1a and 1b typically found in the United States and Europe, genotype 4 in Africa and the Middle East, genotypes 5 and 6 in Southeast Asia and South Africa). Response to interferon therapy depends on HCV genotype.
References in periodicals archive ?
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons [alpha]-2a and [alpha]-2b, plus ribavirin.
Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience.
IL-28B genetic variation, gender, age, jaundice, hepatitis C virus genotype, and hepatitis B virus and HIV co-infection in spontaneous clearance of hepatitis C virus.
Hepatitis C virus genotype distribution in Egyptian diabetic patients: a preliminary study.
The POLARIS-1 study has evaluated Vosevi for 12 weeks in adults with hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 with or without compensated cirrhosis who had failed prior treatment with an NS5A inhibitor-containing regimen.
Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: treatment response, side effects and future prospective.
According to Inoue et al., in blood transfusion unit about 2.1% were infected with HCV.4 In Indonesia, a study in several hospitals of Jakarta, reported that hepatitis C virus genotype 1 is the most prevalent about 72.7%, composed of subtype 1b 47.3%, subtype 1c 18.7% and subtype 1a 6.7%.5
Hepatitis C virus genotype subtypes prevalence within transmission route groups Presentation of HCV-genotype Sig.
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial.